CAI
CAI
NASDAQ · Biotechnology

Caris Life Sciences Inc

$18.56
-0.68 (-3.53%)
As of Mar 25, 9:50 PM ET ·
Financial Highlights (FY 2026)
Revenue
396.63M
Net Income
-271,195,406
Gross Margin
43.8%
Profit Margin
-68.4%
Rev Growth
D/E Ratio
0.79
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 43.8% 50.6% 50.6% 50.6%
Operating Margin -62.4% 21.1% 22.1% 19.6%
Profit Margin -68.4% 19.3% 20.1% 16.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 396.63M 1.64B 1.52B 1.76B
Gross Profit 173.61M 830.36M 769.23M 889.64M
Operating Income -247,379,360 345.95M 336.69M 344.80M
Net Income -271,195,406 316.28M 306.08M 281.70M
Gross Margin 43.8% 50.6% 50.6% 50.6%
Operating Margin -62.4% 21.1% 22.1% 19.6%
Profit Margin -68.4% 19.3% 20.1% 16.0%
Rev Growth +14.2% +10.8% -1.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.30B 1.38B 1.27B 1.60B
Total Equity 1.65B 5.23B 4.48B 5.40B
D/E Ratio 0.79 0.26 0.28 0.30
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -247,584,132 415.16M 429.14M 456.09M
Free Cash Flow 185.08M 215.40M 287.32M